Robert B West

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6381957/publications.pdf

Version: 2024-02-01

135 papers 20,314 citations

56 h-index 122 g-index

143 all docs

143
docs citations

143 times ranked 30495 citing authors

#	Article	IF	Citations
1	International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. Journal of Neurological Surgery, Part B: Skull Base, 2023, 84, 307-319.	0.8	10
2	Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell, 2022, 185, 299-310.e18.	28.9	161
3	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal of Cancer, 2022, 162, 221-236.	2.8	22
4	Abstract OT1-09-01: A randomized study comparing surgical excision versus N e O adjuvant R adiotherapy followed by delayed surgical excision of D uctal carcinoma I n S itu (NORDIS) . Cancer Research, 2022, 82, OT1-09-01-0T1-09-01.	0.9	0
5	Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.8	O
6	The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-Î ² B signaling. Science Advances, 2022, 8, eabh2445.	10.3	10
7	Mesenchymal tumor cells drive adaptive resistance of <i>Trp53^{â^'/â^'}</i> breast tumor cells to inactivated mutant <i>Kras</i> . Molecular Oncology, 2022, 16, 3128-3145.	4.6	1
8	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nature Communications, 2021, 12, 117.	12.8	34
9	Unmasking the immune microecology of ductal carcinoma in situ with deep learning. Npj Breast Cancer, 2021, 7, 19.	5.2	20
10	Transcriptome and genome evolution during HER2-amplified breast neoplasia. Breast Cancer Research, 2021, 23, 73.	5.0	2
11	Acinar cell clonal expansion in pancreas homeostasis and carcinogenesis. Nature, 2021, 597, 715-719.	27.8	29
12	Self-Organizing Maps for Cellular In Silico Staining and Cell Substate Classification. Frontiers in Immunology, 2021, 12, 765923.	4.8	5
13	Oncogene-mediated metabolic gene signature predicts breast cancer outcome. Npj Breast Cancer, 2021, 7, 141.	5. 2	20
14	Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nature Communications, 2021, 12, 6726.	12.8	101
15	Gene Expression Profiling of Head and Neck Tumors Identifies FOXP1 and SOX10 Expression as Useful for Distinguishing Ameloblastoma From Basaloid Salivary Gland Tumors. American Journal of Surgical Pathology, 2020, 44, 665-672.	3.7	3
16	Origins and clonal convergence of gastrointestinal IgE ⁺ B cells in human peanut allergy. Science Immunology, 2020, 5, .	11.9	88
17	Integrating genomic features for non-invasive early lung cancer detection. Nature, 2020, 580, 245-251.	27.8	379
18	HER2 Dual In Situ Hybridization: Correlations and Cautions. Archives of Pathology and Laboratory Medicine, 2020, 144, 1525-1534.	2.5	4

#	Article	IF	Citations
19	Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis. Modern Pathology, 2020, 33, 1518-1526.	5.5	16
20	Clinical vs genomic risks in breast cancer in 2019: Breast pathologist's appellate review of the controversial results from TAILORx trial. Breast Journal, 2020, 26, 1447-1448.	1.0	0
21	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
22	Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. Haematologica, 2020, 105, e129-e132.	3.5	11
23	Abstract OT3-09-04: A randomized phase II study comparing surgical excision versusNeOadjuvantRadiotherapy followed by delayed surgical excision ofDuctal carcinomaln Situ (NORDIS). , 2020, , .		1
24	Abstract 6669: Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma. , 2020, , .		0
25	A multi-scale integrated analysis identifies KRT8 as a pan-cancer early biomarker. , 2020, , .		6
26	Genomic landscape of ductal carcinoma in situ and association with progression. Breast Cancer Research and Treatment, 2019, 178, 307-316.	2.5	17
27	MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma. Oral Oncology, 2019, 98, 147-155.	1.5	18
28	MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure. Science Advances, 2019, 5, eaax5851.	10.3	252
29	Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ. Genome Research, 2019, 29, 1816-1825.	5.5	102
30	Cell cycle progression in confining microenvironments is regulated by a growth-responsive TRPV4-PI3K/Akt-p27 ^{Kip1} signaling axis. Science Advances, 2019, 5, eaaw6171.	10.3	107
31	Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Cancer, 2019, 125, 3225-3233.	4.1	18
32	YAP-independent mechanotransduction drives breast cancer progression. Nature Communications, 2019, 10, 1848.	12.8	127
33	Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clinical Lung Cancer, 2019, 20, e356-e361.	2.6	1
34	Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nature Communications, 2019, 10, 657.	12.8	43
35	Most canine ameloblastomas harbor HRAS mutations, providing a novel large-animal model of RAS-driven cancer. Oncogenesis, $2019, 8, 11$.	4.9	19
36	The HTN3-MSANTD3 Fusion Gene Defines a Subset of Acinic Cell Carcinoma of the Salivary Gland. American Journal of Surgical Pathology, 2019, 43, 489-496.	3.7	52

#	Article	IF	CITATIONS
37	Spatial integration of radiology and pathology images to characterize breast cancer aggressiveness on pre-surgical MRI., 2019,,.		1
38	Framework for the co-registration of MRI and histology images in prostate cancer patients with radical prostatectomy, , 2019, , .		4
39	Genomic analysis of benign prostatic hyperplasia implicates cellular relandscaping in disease pathogenesis. JCI Insight, 2019, 4, .	5.0	26
40	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 2851-2858.	7.0	65
41	Matrix mechanical plasticity regulates cancer cell migration through confining microenvironments. Nature Communications, 2018, 9, 4144.	12.8	263
42	A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell, 2018, 174, 1373-1387.e19.	28.9	729
43	<i>GFPT2</i> -Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. Cancer Research, 2018, 78, 3445-3457.	0.9	7 5
44	Abstract 185: p300 and STAT3 drive YAP-independent mechanotransduction during breast cancer invasion. , 2018, , .		0
45	Abstract 4749: VISTA immune checkpoint deregulation in human triple-negative breast cancer. , 2018, , .		0
46	Abstract 3411: Biological subtypes of nasopharyngeal carcinoma by genomic profiling., 2018,,.		0
47	(S012) Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. International Journal of Radiation Oncology Biology Physics, 2017, 98, E4.	0.8	0
48	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	9.4	701
49	Genome-wide reconstruction of complex structural variants using read clouds. Nature Methods, 2017, 14, 915-920.	19.0	96
50	â€~Non-classical' HER2 FISH results in breast cancer: a multi-institutional study. Modern Pathology, 2017, 30, 227-235.	5.5	79
51	Role of <i>KEAP1</i> /i>NRF2 and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discovery, 2017, 7, 86-101.	9.4	239
52	Local estrogen axis in the human bone microenvironment regulates estrogenÂreceptor-positiveÂbreast cancer cells. Breast Cancer Research, 2017, 19, 121.	5.0	20
53	Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma. PLoS ONE, 2017, 12, e0171265.	2.5	39
54	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	2.3	19

#	Article	IF	CITATIONS
55	BRAF inhibitor therapy of primary ameloblastoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 122, 518-519.	0.4	9
56	BRAF inhibitor treatment of primary BRAF -mutant ameloblastoma with pathologic assessment of response. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 122, e5-e7.	0.4	64
57	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	17.5	837
58	Ameloblastoma: a clinical review and trends in management. European Archives of Oto-Rhino-Laryngology, 2016, 273, 1649-1661.	1.6	156
59	Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. Breast Cancer Research, 2015, 17, 108.	5.0	19
60	Fast and scalable inference of multi-sample cancer lineages. Genome Biology, 2015, 16, 91.	8.8	180
61	Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia. Genome Medicine, 2015, 7, 28.	8.2	17
62	Automated Analysis and Classification of Histological Tissue Features by Multi-Dimensional Microscopic Molecular Profiling. PLoS ONE, 2015, 10, e0128975.	2.5	22
63	The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 2015, 21, 938-945.	30.7	2,505
64	Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2015, 10, 500-508.	1.1	129
65	Novel Mutations in Neuroendocrine Carcinoma of the Breast. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 97-103.	1.2	48
66	Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clinical Cancer Research, 2015, 21, 3501-3511.	7.0	129
67	Read clouds uncover variation in complex regions of the human genome. Genome Research, 2015, 25, 1570-1580.	5.5	70
68	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non–Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv211.	6.3	64
69	Read Clouds Uncover Variation in Complex Regions of the Human Genome. Lecture Notes in Computer Science, 2015, , 30-31.	1.3	0
70	Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers. Cancer Research, 2015, 75, PR09-PR09.	0.9	3
71	GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Research, 2015, 35, 669-76.	1.1	5
72	Molecular pathological analysis of sarcomas using paraffinâ€embedded tissue: current limitations and future possibilities. Histopathology, 2014, 64, 163-170.	2.9	17

#	Article	IF	CITATIONS
73	Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients. Head and Neck, 2014, 36, 709-714.	2.0	48
74	NF-κB protein expression associates with 18F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism. Lung Cancer, 2014, 83, 189-196.	2.0	51
75	Stromal signatures in endometrioid endometrial carcinomas. Modern Pathology, 2014, 27, 631-639.	5.5	23
76	Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation. Cancer Research, 2014, 74, 341-352.	0.9	30
77	Fingerprints of Epstein-Barr virus in nasopharyngeal carcinoma. Nature Genetics, 2014, 46, 809-810.	21.4	5
78	Discovery of recurrent structural variants in nasopharyngeal carcinoma. Genome Research, 2014, 24, 300-309.	5.5	32
79	A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions. Genome Biology, 2014, 15, R71.	9.6	30
80	Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nature Genetics, 2014, 46, 722-725.	21.4	273
81	Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. Journal of Clinical Investigation, 2014, 124, 5275-5290.	8.2	81
82	Abstract 3436: Ameloblastoma driver mutations revealed by next-generation sequencing of formalin-fixed paraffin-embedded specimens. , 2014, , .		0
83	MAST2 and NOTCH1 translocations in breast carcinoma and associated pre-invasive lesions. Human Pathology, 2013, 44, 2837-2844.	2.0	14
84	Inference of Tumor Phylogenies with Improved Somatic Mutation Discovery. Journal of Computational Biology, 2013, 20, 933-944.	1.6	45
85	Genome evolution during progression to breast cancer. Genome Research, 2013, 23, 1097-1108.	5.5	98
86	Stromal Responses among Common Carcinomas Correlated with Clinicopathologic Features. Clinical Cancer Research, 2013, 19, 5127-5135.	7.0	16
87	Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer. Breast Cancer Research, 2013, 15, R117.	5.0	14
88	Desktop Transcriptome Sequencing From Archival Tissue to Identify Clinically Relevant Translocations. American Journal of Surgical Pathology, 2013, 37, 796-803.	3.7	17
89	Sox10 and S100 in the Diagnosis of Soft-tissue Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 445-450.	1.2	250
90	Biphasic Papillary and Lobular Breast Carcinoma With PIK3CA and IDH1 Mutations. Diagnostic Molecular Pathology, 2012, 21, 221-224.	2.1	13

#	Article	IF	Citations
91	Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. Modern Pathology, 2012, 25, 930-937.	5.5	39
92	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 929-934.	7.1	239
93	Pathologic Features and Immunophenotype of Estrogen Receptor–positive Breast Cancers in BRCA1 Mutation Carriers. American Journal of Surgical Pathology, 2012, 36, 1483-1488.	3.7	11
94	Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biology, 2012, 13, R75.	9.6	221
95	ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. Journal of Pathology, 2012, 227, 223-233.	4.5	77
96	Detection of Long Non-Coding RNA in Archival Tissue: Correlation with Polycomb Protein Expression in Primary and Metastatic Breast Carcinoma. PLoS ONE, 2012, 7, e47998.	2.5	125
97	MYB Expression and Translocation in Adenoid Cystic Carcinomas and Other Salivary Gland Tumors With Clinicopathologic Correlation. American Journal of Surgical Pathology, 2011, 35, 92-99.	3.7	248
98	Immunohistochemical Distinction of Primary Adrenal Cortical Lesions From Metastatic Clear Cell Renal Cell Carcinoma. American Journal of Surgical Pathology, 2011, 35, 678-686.	3.7	115
99	Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. Journal of Pathology, 2011, 225, 574-582.	4.5	20
100	Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival. Science Translational Medicine, 2011, 3, 108ra113.	12.4	603
101	Endogenous Versus Tumor-Specific Host Response to Breast Carcinoma: A Study of Stromal Response in Synchronous Breast Primaries and Biopsy Site Changes. Clinical Cancer Research, 2011, 17, 437-446.	7.0	7
102	Expression Profiling in Soft Tissue Sarcomas With Emphasis on Synovial Sarcoma, Gastrointestinal Stromal Tumor, and Leiomyosarcoma. Advances in Anatomic Pathology, 2010, 17, 366-373.	4.3	22
103	DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2 Different Antibodies. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 333-337.	1.2	69
104	Genomeâ€wide transcriptome analyses reveal p53 inactivation mediated loss of miRâ€34a expression in malignant peripheral nerve sheath tumours. Journal of Pathology, 2010, 220, 58-70.	4.5	106
105	Variations in stromal signatures in breast and colorectal cancer metastases. Journal of Pathology, 2010, 222, 158-165.	4.5	32
106	Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 2010, 464, 1071-1076.	27.8	4,648
107	Translating Gene Expression Into Clinical Care: Sarcomas As a Paradigm. Journal of Clinical Oncology, 2010, 28, 1796-1805.	1.6	42
108	3′-End Sequencing for Expression Quantification (3SEQ) from Archival Tumor Samples. PLoS ONE, 2010, 5, e8768.	2.5	123

#	Article	IF	CITATIONS
109	Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Case Reports in Oncology, 2009, 2, 242-250.	0.7	6
110	Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract. American Journal of Physiology - Renal Physiology, 2009, 296, G1370-G1381.	3.4	320
111	The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma. Clinical Cancer Research, 2009, 15, 778-787.	7.0	177
112	A compact VEGF signature associated with distant metastases and poor outcomes. BMC Medicine, 2009, 7, 9.	5 . 5	162
113	Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Modern Pathology, 2009, 22, 914-921.	5.5	76
114	External Beam Radiation Therapy Enhances Local Control in Pigmented Villonodular Synovitis. International Journal of Radiation Oncology Biology Physics, 2009, 75, 183-187.	0.8	57
115	Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. American Journal of Pathology, 2009, 174, 2347-2356.	3.8	83
116	Microtubule-associated Protein-2 is a Sensitive Marker of Primary and Metastatic Neuroblastoma. American Journal of Surgical Pathology, 2009, 33, 1695-1704.	3.7	19
117	The fibromatosis signature defines a robust stromal response in breast carcinoma. Laboratory Investigation, 2008, 88, 591-601.	3.7	100
118	Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Modern Pathology, 2008, 21, 531-539.	5.5	71
119	Diagnostic Implications of Podoplanin Expression in Peripheral Nerve Sheath Neoplasms. American Journal of Clinical Pathology, 2008, 129, 886-893.	0.7	46
120	Immunohistochemical and Biogenetic Features of Diffuse-Type Tenosynovial Giant Cell Tumors: The Potential Roles of Cyclin A, P53, and Deletion of 15q in Sarcomatous Transformation. Clinical Cancer Research, 2008, 14, 6023-6032.	7.0	20
121	A Novel Monoclonal Antibody Against DOG1 is a Sensitive and Specific Marker for Gastrointestinal Stromal Tumors. American Journal of Surgical Pathology, 2008, 32, 210-218.	3.7	399
122	Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides. American Journal of Surgical Pathology, 2007, 31, 970-976.	3.7	199
123	Experimental approaches to the study of cancer–stroma interactions: recent findings suggest a pivotal role for stroma in carcinogenesis. Laboratory Investigation, 2007, 87, 967-970.	3.7	28
124	The Stanford Tissue Microarray Database. Nucleic Acids Research, 2007, 36, D871-D877.	14.5	80
125	A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 690-695.	7.1	474
126	Nuclear beta-catenin in mesenchymal tumors. Modern Pathology, 2005, 18, 68-74.	5 . 5	268

#	Article	IF	CITATIONS
127	TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Modern Pathology, 2005, 18, 1641-1648.	5.5	37
128	The gene expression profile of extraskeletal myxoid chondrosarcoma. Journal of Pathology, 2005, 206, 433-444.	4.5	65
129	Determination of Stromal Signatures in Breast Carcinoma. PLoS Biology, 2005, 3, e187.	5.6	180
130	Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene, 2004, 23, 7780-7790.	5.9	137
131	CD117 expression in mesothelioma. Modern Pathology, 2004, 17, 1021-1021.	5 . 5	5
132	The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status. American Journal of Pathology, 2004, 165, 107-113.	3.8	593
133	Apo D in Soft Tissue Tumors. American Journal of Surgical Pathology, 2004, 28, 1063-1069.	3.7	81
134	Tissue Microarray Validation of Epidermal Growth Factor Receptor and SALL2 in Synovial Sarcoma with Comparison to Tumors of Similar Histology. American Journal of Pathology, 2003, 163, 1449-1456.	3.8	133
135	The Usefulness of Immunohistochemistry in the Diagnosis of Follicular Lymphoma in Bone Marrow Biopsy Specimens. American Journal of Clinical Pathology, 2002, 117, 636-643.	0.7	32